FibroGen (NASDAQ:FGEN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.
Insider & Institutional Ownership
72.7% of FibroGen shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 2.0% of FibroGen shares are owned by company insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for FibroGen and Unicycive Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FibroGen | 0 | 1 | 0 | 0 | 2.00 |
| Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Profitability
This table compares FibroGen and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FibroGen | -67.66% | N/A | -36.17% |
| Unicycive Therapeutics | N/A | N/A | -29.88% |
Valuation and Earnings
This table compares FibroGen and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FibroGen | $147.75 million | 0.24 | -$284.23 million | ($1.23) | -0.29 |
| Unicycive Therapeutics | $680,000.00 | 122.04 | -$30.54 million | ($0.97) | -0.82 |
Unicycive Therapeutics has lower revenue, but higher earnings than FibroGen. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
FibroGen has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500.
Summary
Unicycive Therapeutics beats FibroGen on 11 of the 14 factors compared between the two stocks.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
